Recently, Healthcare Executivereleased the 2024 Top 100 China Pharmaceutical Innovation Companies, where Hansoh Pharma maintains its position in the first tier for the sixth consecutive year.
The "Top 100 China Pharmaceutical Innovators" ranking, compiled byHealthcare Executivebased on Clarivate Derwent Innovation™ patent data and Cortellis™ competitive intelligence and clinical trial data, is selected based on innovation foundation, process, and outcomes, while evaluating the numbers of authorized patents, patent citations, clinical trials, and innovative drugs approved and launched. This is the sixth timeHealthcare Executivehas released the "Top 100 China Pharmaceutical Innovators" ranking, and also the sixth consecutive year that Hansoh Pharma has been included in the "first tier".
In 2024, Hansoh Pharma has adhered to the dualengine strategy driven by both in-house R&D and external BD collaboration. With a continued focus on the oncology sector, the companycompany explores global pipeline potentials whileexpanding into fields such as anti-infection, central nervous system disorders, metabolic diseases, and autoimmune condition. Currently, Hansoh Pharma has over 30 innovative drugs in more than 50 clinical trials,with key progress made in several major product developments. The company has launched 7 innovative drugs, and all 9 indications included in the national medical insurance directory.
In terms of internationalization, the company has established 11 collaborative projects to enrich its high-potential innovation pipeline, completed 2 external authorization licenses, striving to benefit global patients with the company's innovative achievements.
As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma has consistently ranked among the top three in "China's Best Industrial Enterprises in Pharmaceutical R&D Product Pipeline " for many years. The company has been granted over 600 patents, both domestically and internationally, and has received two Second Class Prizes for National Science and Technology Progress, and two China Patent Gold Awards. Hansoh Pharma is committed to high-quality innovation and outstanding operations, actively partnering with global partners to enhance human quality of life through more groundbreaking therapeutic innovations.
